Skripsi
DEFINED DAILY DOSE PENGGUNAAN ALLOPURINOL DI PUSKESMAS 4 ULU KOTA PALEMBANG
Background: Gout is a chronic condition caused by the accumulation of monosodium urate (MSU) crystals due to hyperuricemia, often associated with a diet high in purines, obesity, and other metabolic disorders. Allopurinol is the first-line drug used to lower serum uric acid levels in gout patients. Ensuring the correct dosage of allopurinol is essential to enhance therapeutic effectiveness and prevent unwanted side effects. Methods: This study aimed to evaluate the use of allopurinol at the 4 Ulu Public Health Center in Palembang during 2024 using the Defined Daily Dose (DDD) method, an international standard for measuring rational drug use. The study employed a descriptive retrospective design utilizing secondary data from patient medical records of those receiving allopurinol therapy throughout 2024. The DDD calculation was performed to assess the rationality of allopurinol use at the center. Results: Allopurinol use at the 4 Ulu Public Health Center was 0.055 DDD per 1000 patients per day. The highest usage was recorded in January (0.1 DDD), while the lowest usage was in August (0.021 DDD). Based on the DDD calculation, allopurinol use at the center was classified as underuse, indicating that the use of the drug was still low compared to the prevalence of gout, which amounted to 327 cases in 2024. Conclussion: The conclusion of this study is that the use of allopurinol at the 4 Ulu Public Health Center is relatively low compared to the gout prevalence. Factors contributing to this underuse include limited access to medication, low awareness of long-term therapy, and potential delays in diagnosis. This study is expected to provide valuable insights for healthcare providers to raise awareness of rational allopurinol use in accordance with therapeutic guidelines. Keywords: Gout, Allopurinol, DDD
| Title | Edition | Language |
|---|---|---|
| POLA PENGGUNAAN ALLOPURINOL PADA PASIEN GOUT ARTRITIS DI PUSKESMAS SEKIP PALEMBANG PERIODE 1 JULI 2021 - 30 JUNI 2022 | id |